Contact this trialFirst, we need to learn more about you.
Cancer Vaccine
Vaccine Nous-209 for Lynch Syndrome
Recruiting1 awardPhase 1 & 2
Philadelphia, Pennsylvania
This trial tests the safety and effectiveness of the Nous-209 vaccine in patients with Lynch syndrome, a condition that increases cancer risk. The vaccine uses man-made proteins to help the immune system recognize and fight cancer cells. Researchers aim to see if the vaccine can prevent cancer development in these high-risk patients. Nous-209 is a ready-to-use cancer vaccine that targets specific markers found in certain types of tumors.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service